Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 27, 2020, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 27, 2020, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg.".